CASE/0443/01/25 - Complainant v Organon

Allegations about the promotion of NuvaRing to the public

  • Case number
    CASE/0443/01/25
  • Complaint received
    20 January 2025
  • Completed
    04 July 2025
  • Appeal hearing
    No appeal
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Additional sanctions

Case Summary

This case was in relation to a three-page leaflet produced by Organon titled “What are my contraceptive options?”. The complainant alleged that, by listing advantages of the contraceptive vaginal ring as a contraceptive option, the leaflet constituted promotion of Organon’s NuvaRing (etonogestrel/ethinyl estradiol) vaginal ring to the public. The complainant also alleged that Organon should have self-reported this as a breach of the Code.

The outcome under the 2021 Code was:

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 3.4

Requirement that companies must comply with all applicable codes, laws and regulations to which they are subject

No Breach of Clause 5.1

Requirement to maintain high standards at all times

No Breach of Clause 26.1

Requirement not to advertise prescription only medicines to the public

This summary is not intended to be read in isolation.
For full details, please see the full case report below.